CS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment Offering
CS Diagnostics Corp. (OTCQB:CSDX) launched a Regulation D, Rule 506(c) offering on October 13, 2025, selling CSDX Preferred C Shares to U.S. accredited and non-U.S. investors to fund commercialization of CS Protect Hydrogel and MEDUSA.
Net proceeds are planned to be allocated roughly: Regulatory 20–25%, Manufacturing 15–20%, Sales & Marketing 20–25%, R&D 10–15%, Working capital 10–15%, and Token/platform support 5–10%. Offering documents (PPM, Subscription Agreement) are available on the company website.
CS Diagnostics Corp. (OTCQB:CSDX) ha lanciato un'offerta Regolamentare D, Regola 506(c) il 13 ottobre 2025, vendendo CSDX Preferred C Shares a investitori accreditati statunitensi e non statunitensi per finanziare la commercializzazione di CS Protect Hydrogel e MEDUSA.
I proventi netti sono previsti di essere assegnati approssimativamente come: Regolamentare 20–25%, Produzione 15–20%, Vendite e Marketing 20–25%, R&S 10–15%, Capitale di lavoro 10–15%, e Sostegno token/piattaforma 5–10%. I documenti dell'offerta (PPM, Accordo di Sottoscrizione) sono disponibili sul sito della società.
CS Diagnostics Corp. (OTCQB:CSDX) lanzó una oferta de Regla D, Regla 506(c) el 13 de octubre de 2025, vendiendo CSDX Preferred C Shares a inversores acreditados de EE. UU. y no estadounidenses para financiar la comercialización de CS Protect Hydrogel y MEDUSA.
Los ingresos netos se asignarán aproximadamente como: Regulatorio 20–25%, Fabricación 15–20%, Ventas y Marketing 20–25%, I+D 10–15%, Capital de trabajo 10–15%, y Soporte de tokens/plataforma 5–10%. Los documentos de la oferta (PPM, Acuerdo de Suscripción) están disponibles en el sitio web de la empresa.
CS Diagnostics Corp. (OTCQB:CSDX) 는 2025년 10월 13일 Regulation D, Rule 506(c) 공모를 시작했으며 CSDX Preferred C Shares 를 미국 공인 투자자 및 미국 외 투자자들에게 판매하여 CS Protect Hydrogel 및 MEDUSA 의 상용화를 자금을 조달합니다.
순수 조달금은 대략적으로 다음과 같이 배분될 예정입니다: Regulatory 20–25%, Manufacturing 15–20%, Sales & Marketing 20–25%, R&D 10–15%, Working capital 10–15%, Token/platform support 5–10%. 공모 문서(PPM, Subscription Agreement)는 회사 웹사이트에서 이용 가능합니다.
CS Diagnostics Corp. (OTCQB:CSDX) a lancé une offre Regulation D, Rule 506(c) le 13 octobre 2025, en vendant des CSDX Preferred C Shares à des investisseurs accrédités américains et non américains afin de financer la mise sur le marché de CS Protect Hydrogel et MEDUSA.
Le produit net est prévu d’être attribué approximativement comme suit : Réglementaire 20–25%, Fabrication 15–20%, Ventes & Marketing 20–25%, R&D 10–15%, Capitaux propres de fonctionnement 10–15%, et Soutien token/plateforme 5–10%. Les documents d’offre (PPM, accord de souscription) sont disponibles sur le site de l’entreprise.
CS Diagnostics Corp. (OTCQB:CSDX) hat am 13. Oktober 2025 ein Regulation D, Rule 506(c) Angebot gestartet und CSDX Preferred C Shares an in den USA akkreditierte und nicht-akkreditierte Investoren verkauft, um die Kommerzialisierung von CS Protect Hydrogel und MEDUSA zu finanzieren.
Nettogesamtsmittel sollen ungefähr wie folgt zugewiesen werden: Regulatory 20–25%, Manufacturing 15–20%, Sales & Marketing 20–25%, R&D 10–15%, Working capital 10–15%, und Token/platform support 5–10%. Angebotsunterlagen (PPM, Subscription Agreement) sind auf der Unternehmenswebsite erhältlich.
CS Diagnostics Corp. (OTCQB:CSDX) أطلقت عرض Regulation D، القاعدة 506(c) في 13 أكتوبر 2025، ببيع CSDX Preferred C Shares لمستثمرين معتمدين في الولايات المتحدة وغير أمريكيين لتمويل تسويق CS Protect Hydrogel و MEDUSA.
سيتم تخصيص العائدات الصافية تقريباً كما يلي: Regulatory 20–25%، Manufacturing 15–20%، Sales & Marketing 20–25%، R&D 10–15%، Working capital 10–15%، و Token/platform support 5–10%. وثائق العرض (PPM، اتفاق الاشتراك) متاحة على موقع الشركة.
CS Diagnostics Corp. (OTCQB:CSDX) 于 2025 年 10 月 13 日启动 Regulation D、Rule 506(c) 发售，向美国认证投资者和非美国投资者出售 CSDX Preferred C Shares，以资助 CS Protect Hydrogel 与 MEDUSA 的商业化。
净收益拟大致分配如下： Regulatory 20–25%、 Manufacturing 15–20%、 Sales & Marketing 20–25%、 R&D 10–15%、 Working capital 10–15%、 和 Token/platform support 5–10%。发售文件（PPM、订阅协议）可在公司网站获取。
- Regulatory funding allocation ~20–25% to support approvals
- Commercial scaling funding: manufacturing 15–20% and sales 20–25%
- R&D support allocation ~10–15% for product optimization
- Issuance of CSDX Preferred C Shares represents a capital structure change
- Up to 5–10% of proceeds earmarked for token/platform support instead of core operations
CHEYENNE, WYOMING / ACCESS Newswire / October 13, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) today announced the official launch of its Regulation D, Rule 506(c) investment offering (the "Offering"), marking an important milestone in the company's ongoing mission to enhance patient safety and health outcomes through advanced medical technologies.
CS Diagnostics Corp. is a global medical technology company dedicated to innovation in healthcare safety and performance. The company's core products include:
CS Protect Hydrogel - a next-generation tissue spacer gel designed to improve precision and reduce complications in radiotherapy.
MEDUSA - a proprietary advanced surface disinfectant system that delivers effective and scalable infection control for clinical and industrial environments.
Offering Overview
The Offering is open exclusively to U.S. accredited investors and all other non-U.S. investors, providing the opportunity to participate in CS Diagnostics Corp.'s growth through the purchase of CSDX Preferred C Shares.
Proceeds from the Offering will support the commercialization and scaling of CS Protect Hydrogel and MEDUSA, advancing the company's efforts toward broad regulatory approval, global market deployment, and sustainable profitability.
This Offering structure enables investors to align with a high-growth MedTech enterprise, combining traditional equity potential with participation in a company committed to regulatory compliance, transparency, and long-term value creation.
Use of Proceeds
Net proceeds from the Offering are expected to be allocated approximately as follows:
Purpose | Allocation (Approx.) | Description |
|---|---|---|
Regulatory & filing costs (U.S.) | ~20-25 % | FDA / EPA / patent filings, third-party consulting, legal advisory fees, and regulatory compliance marketing. |
Manufacturing scale-up & quality control | ~15-20 % | Building production capacity, supplier agreements, QA/QC systems, and compliance with global safety standards. |
Sales & marketing infrastructure (U.S. & global) | ~20-25 % | Deployment of commercial teams, marketing campaigns, trade shows, and international distribution partnerships. |
Research & development enhancements | ~10-15 % | Product optimization, safety/effectiveness testing, and development of adjacent innovations. |
Working capital & administrative expenses | ~10-15 % | Staffing, legal, audit, accounting, and corporate overhead. |
Token / platform support, security & compliance | ~5-10 % | Blockchain infrastructure, token issuance, investor accreditation (KYC/AML), and cybersecurity audits. |
Investor Access and Additional Information
Prospective investors can review the full details of the Offering - including the Private Placement Memorandum (PPM), Subscription Agreement, and Investor Questionnaire - by visiting the company's website at www.csdcorp.us.
"We are advancing according to plan. While we believe CSDX may currently be undervalued, our strategic roadmap and execution focus position us for substantial growth and long-term investor returns," said Mohammad Essayed, Chief Financial Officer of CS Diagnostics Corp.
"This Offering marks a pivotal step in our company's journey to bring transformative medical technologies to market," said Thomas Fahrhoefer, President of CS Diagnostics Corp. board of directors "Our mission has always been clear - to innovate solutions that directly enhance patient safety and healthcare outcomes. With CS Protect Hydrogel and MEDUSA, we are addressing critical needs in radiotherapy precision and infection control, two areas that directly impact millions of patients worldwide."
Forward-Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
Actual results achieved may vary from the information provided herein because of numerous known and unknown risks, uncertainties, and other factors.
For further information please visit https://csdcorp.us
or contact
Mohammad Essayed
Email: investment@csdcorp.us
SOURCE: CS Diagnostics Corp.
View the original press release on ACCESS Newswire
FAQ
What is CS Diagnostics (CSDX) offering announced on October 13, 2025?
How will proceeds from the CSDX offering be used?
Who is eligible to invest in the CSDX Regulation D, Rule 506(c) offering?
Where can investors find the CSDX Private Placement Memorandum and subscription documents?
What products will the CSDX offering proceeds specifically support?
